Drug Science (UK) has selected an African company as its supplier for its medical cannabis-focused clinical research initiative, Project Twenty21. The business in question: MG Health Limited, from the Kingdom of Lesotho.
According to the companies, Project Twenty21will target 20,000 U.K.-based patients suffering from chronic pain, anxiety disorder, epilepsy, multiple sclerosis, Post Traumatic Stress Disorder; substance use disorder and Tourette’s Syndrome. Researchers will look into the potential benefits of medical cannabis for the treatment of said conditions.
Francois Ferreira, COO of MG Health told Benzinga he thinks Project Twenty21 is a “bold initiative.” He noted his company sees this study as “a significant step toward collecting data from a large group of patients.
“This study will help validate the large body of anecdotal evidence regarding the therapeutic benefits of medical cannabis. We believe that our industry has an equally important role in helping to dispel some of the exaggerated claims and distracting myths surrounding the product,” he said.
Adding to these comments, David Badcock, CEO of U.K.-based Drug Science explained Project Twenty21 does not offer a short-cut to accessing medical cannabis in the U.K.
“Patients will need to be seen by a physician, and provided their medical indication can be addressed by medical cannabis, and cannot be addressed with an existing treatment, the doctor may give the patient a prescription for medical cannabis,” he said.
Each individual prescription still needs to be approved by the Home Office, on a “single prescription per single patient” basis, before the pharmacy is allowed to source the product and dispense it to the patient.
Acknowledging this is “a very slow and cumbersome process,” he hopes access to cannabis products, when appropriate, “will become a little easier as Project T21 is able to provide feedback to the authorities and participating prescribers.”
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.